Predicts overall and progression-free survival in diffuse large B-cell lymphoma (DLBCL) based on five independent risk factors. The original IPI (International Prognostic Index) was developed in the pre-rituximab era and identifies four risk groups based on age, performance status, disease stage, LDH level, and extranodal involvement. The R-IPI (Revised IPI) was developed for the rituximab era to better discriminate outcomes in patients receiving R-CHOP therapy, redistributing patients into three prognostic groups with improved clinical utility. Both indices provide valuable prognostic information for treatment planning, clinical trial stratification, and patient counseling in DLBCL management.
Awaiting Clinical Input
Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.
The International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.
Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.
Score 0-1 points
Score 2 points
Score 3 points
Score 4-5 points
Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.
Open in Web AppClinical Decision Support (CDS) Notice & Legal Disclaimer
This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.